Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

MLA

Bourlon, Maria Teresa, et al. “Nivolumab plus Cabozantinib (N+C) vs Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (ARCC): Results from 55-Month Follow-up of the CheckMate 9ER Trial.” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 362. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.4_suppl.362.

APA

Bourlon, M. T., Escudier, B., Burotto, M., Powles, T., Apolo, A. B., Shah, A. Y., Porta, C., Suárez, C., Barrios, C. H., Richardet, M., Gurney, H., Kessler, E. R., Tomita, Y., Bedke, J., Wang, F., Wang, P., Panzica, J., Fedorov, V., Motzer, R. J., & Choueiri, T. K. (2024). Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial. Journal of Clinical Oncology, 42, 362. https://doi.org/10.1200/JCO.2024.42.4_suppl.362

Chicago

Bourlon, Maria Teresa, Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, Amishi Yogesh Shah, Camillo Porta, et al. 2024. “Nivolumab plus Cabozantinib (N+C) vs Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (ARCC): Results from 55-Month Follow-up of the CheckMate 9ER Trial.” Journal of Clinical Oncology 42 (February): 362. doi:10.1200/JCO.2024.42.4_suppl.362.